<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2021-3-57-61</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1149</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Значение бессимптомной гиперурикемии при анкилозирующем спондилите</article-title><trans-title-group xml:lang="en"><trans-title>Significance of asymptomatic hyperuricemia in ankylosing spondylitis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1550-8213</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балабанова</surname><given-names>Р. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Balabanova</surname><given-names>R. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Балабанова Римма Михайловна</p><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Rimma Mikhaylovna Balabanova</p><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6354-7244</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ильиных</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ilyinykh</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4190-4471</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подряднова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Podryadnova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4285-0869</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глухова</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Glukhova</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9755-5760</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Урумова</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Urumova</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2021</year></pub-date><volume>15</volume><issue>3</issue><fpage>57</fpage><lpage>61</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Балабанова Р.М., Ильиных Е.В., Подряднова М.В., Глухова С.И., Урумова М.М., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Балабанова Р.М., Ильиных Е.В., Подряднова М.В., Глухова С.И., Урумова М.М.</copyright-holder><copyright-holder xml:lang="en">Balabanova R.M., Ilyinykh E.V., Podryadnova M.V., Glukhova S.I., Urumova M.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1149">https://mrj.ima-press.net/mrj/article/view/1149</self-uri><abstract><p>За последние десятилетия отмечено увеличение частоты бессимптомной гиперурикемии (БГУ), к которой относят повышенный уровень (&gt;360 мкмоль/л) мочевой кислоты (МК) в сыворотке крови у пациентов с отсутствием клинических проявлений подагры. Имеются сообщения о БГУ при различных ревматических заболеваниях. В основном они касаются остеоартрита, при котором БГУ является одним из проявлений метаболического синдрома. Отмечается связь БГУ с легочной гипертензией при системном склерозе; с артериальной гипертензией (АГ) у мужчин с серонегативным ревматоидным артритом; с распространенным кожным псориазом и метаболическими нарушениями при псориатическом артрите. Практически отсутствуют данные о БГУ при анкилозирующем спондилите (АС), что послужило основанием для проведения настоящей работы.</p><p>Цель исследования – оценить ассоциацию БГУ с длительностью и активностью АС и наличием коморбидных заболеваний.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. Проведен ретроспективный анализ 48 историй болезни пациентов с диагностированным АС, находившихся на лечении в ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» с 2015 по 2019 г., у которых уровень МК в сыворотке крови составлял &gt;360 мкмоль/л.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Более половины пациентов с АС и БГУ имели избыточную массу тела, 21% страдали ожирением. У 43,7% пациентов диагностирована АГ. Хроническая болезнь почек II–III стадии выявлена у 16,7% больных, мочекаменная болезнь – у 18,8%. У 4 (8,3%) пациентов имелся сахарный диабет. Уровень МК в сыворотке крови у пациентов с АС составлял 422,0±61,6 мкмоль/л. У больных АС отмечена ассоциация БГУ с возрастом, длительностью и активностью заболевания. Статистически значимой взаимосвязи ГУ с уровнями глюкозы, холестерина, креатинина, индексом массы тела не установлено. При корреляционном анализе обнаружена статистически значимая связь между скоростью клубочковой фильтрации (СКФ) и возрастом пациентов (r=-0,54, p&lt;0,001), длительностью болезни (r=-0,40, р&lt;0,05), уровнем холестерина (r=-0,48, p=0,01), уровнем МК (r=-0,45, p=0,03) и артериальным давлением (r=-0,54, p&lt;0,001). Не наблюдалось связи между активностью болезни и СКФ (p&gt;0,05).</p></sec><sec><title>Заключение</title><p>Заключение. При АС выявлена ассоциация между повышенным уровнем МК в сыворотке крови и длительностью и активностью заболевания, возрастом пациента.</p></sec></abstract><trans-abstract xml:lang="en"><p>Over the past decades, there has been an increase in the incidence of asymptomatic hyperuricemia (AHU), which includes an increased level (&gt;360 μmol/L) of uric acid (UA) in the blood serum of patients with no clinical manifestations of gout. AHU is reported in various rheumatic diseases, mainly in osteoarthritis, in which AHU is one of the manifestations of the metabolic syndrome. There is relationship between AHU and pulmonary hypertension in systemic sclerosis, arterial hypertension (AH) in men with seronegative rheumatoid arthritis, extensive cutaneous psoriasis and metabolic disorders in psoriatic arthritis. There are almost no data on AHU in ankylosing spondylitis (AS), which served objective for this work.</p><sec><title>Objective</title><p>Objective: to assess the association of AHU with AS duration and activity and the presence of comorbid diseases.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. A retrospective analysis of 48 medical histories of patients with diagnosed AS, who were treated in V.A. Nasonova Research Institute of Rheumatology from 2015 to 2019 years, whose serum UA level was &gt;360 μmol/L.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. More than half of patients with AS and AHU were overweight, 21% were obese. AH was diagnosed in 43.7% of patients. Stage II–III chronic kidney disease was detected in 16.7% of patients, urolithiasis – in 18.8%. 4 (8.3%) patients had diabetes mellitus. The serum UA level in patients with AS was 422.0 ± 61.6 μmol/L. In patients with AS, an association between AHU and age, duration and disease activity was noted. There was no statistically significant rela- tionship between HG and blood glucose, cholesterol, creatinine levels, body mass index. Correlation analysis revealed a statistically significant relationship between the glomerular filtration rate (GFR) and the age of patients (r=-0.54, p&lt;0.001), the duration of the disease (r=-0.40, p&lt;0.05), cholesterol level (r=-0.48, p=0.01), UA level (r=-0.45, p=0.03) and blood pressure (r=-0.54, p&lt;0.001). There was no association between disease activity and GFR (p&gt;0.05).</p></sec><sec><title>Conclusion</title><p>Conclusion. In AS, an association between an increased level of UA in the blood serum and the duration and activity of the disease, and patient's age, was established.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мочевая кислота</kwd><kwd>бессимптомная гиперурикемия</kwd><kwd>анкилозирующий спондилит</kwd><kwd>реактивный артрит</kwd><kwd>псориатический артрит</kwd></kwd-group><kwd-group xml:lang="en"><kwd>uric acid</kwd><kwd>asymptomatic hyperuricemia</kwd><kwd>ankylosing spondylitis</kwd><kwd>reactive arthritis</kwd><kwd>psoriatic arthritis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014 Mar;26(2):186-91. doi: 10.1097/BOR.0000000000000028.</mixed-citation><mixed-citation xml:lang="en">Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014 Mar;26(2):186-91. doi: 10.1097/BOR.0000000000000028.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136-41. doi: 10.1002/art.30520.</mixed-citation><mixed-citation xml:lang="en">Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136-41. doi: 10.1002/art.30520.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Roman YM. The Daniel K. Inouye College of Pharmacy Scripts: Perspectives on the Epidemiology of Gout and Hyperuricemia. Hawaii J Med Public Health. 2019 Feb;78(2):71-6.</mixed-citation><mixed-citation xml:lang="en">Roman YM. The Daniel K. Inouye College of Pharmacy Scripts: Perspectives on the Epidemiology of Gout and Hyperuricemia. Hawaii J Med Public Health. 2019 Feb;78(2):71-6.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kim JW, Kwak SG, Lee H, et al. Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015. Rheumatol Int. 2017 Sep; 37(9):1499-506. doi: 10.1007/s00296-017-3768-4. Epub 2017 Jul 4.</mixed-citation><mixed-citation xml:lang="en">Kim JW, Kwak SG, Lee H, et al. Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015. Rheumatol Int. 2017 Sep; 37(9):1499-506. doi: 10.1007/s00296-017-3768-4. Epub 2017 Jul 4.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bardin T, Richette P. Impact of comorbidities on gout and hyperuricemia: an update bon prevalence and treatment options. BMC Med. 2017 Jul 3;15(1):123. doi: 10.1186/s12916-017-0890-9.</mixed-citation><mixed-citation xml:lang="en">Bardin T, Richette P. Impact of comorbidities on gout and hyperuricemia: an update bon prevalence and treatment options. BMC Med. 2017 Jul 3;15(1):123. doi: 10.1186/s12916-017-0890-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Brucato A, Gianci F, Carnovale C. Management of hyperuricemia in asymptomatic patients: a critical appraisal. Eur J Intern Med. 2020 Apr;74:8-17. doi: 10.1016/j.ejim.2020.01.001. Epub 2020 Jan 15.</mixed-citation><mixed-citation xml:lang="en">Brucato A, Gianci F, Carnovale C. Management of hyperuricemia in asymptomatic patients: a critical appraisal. Eur J Intern Med. 2020 Apr;74:8-17. doi: 10.1016/j.ejim.2020.01.001. Epub 2020 Jan 15.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gaffo AL, Edwards NL, Saag RG. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther. 2009;11(4):240. doi: 10.1186/ar2761. Epub 2009 Aug 19.</mixed-citation><mixed-citation xml:lang="en">Gaffo AL, Edwards NL, Saag RG. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther. 2009;11(4):240. doi: 10.1186/ar2761. Epub 2009 Aug 19.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Фомин ВВ, Морозова ТЕ, Цурко ВВ. Гиперурикемия, подагра и высокий кардиоваскулярный риск – как ими управлять в клинической практике. Терапевти- ческий архив. 2019;(12):75-83.</mixed-citation><mixed-citation xml:lang="en">Fomin VV, Morozova TE, Tsurko VV. Hyperuricemia, gout, and high cardiovascular risk. How to manage them in clinical practice. Terapevticheskii arkhiv. 2019;(12): 75-83. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ding X, Zeng C, Wei J, et al. The associations of serum uric acid level and hyperuricemia with knee osteoarthritis. Rheumatol Int. 2016 Apr;36(4):567-73. doi: 10.1007/s00296-015-3418-7. Epub 2016 Jan 7.</mixed-citation><mixed-citation xml:lang="en">Ding X, Zeng C, Wei J, et al. The associations of serum uric acid level and hyperuricemia with knee osteoarthritis. Rheumatol Int. 2016 Apr;36(4):567-73. doi: 10.1007/s00296-015-3418-7. Epub 2016 Jan 7.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo D, Crowson CS, Gabriel SE, et al. Hyperuricemia and incident cardiovascular disease and noncardiac vascular events in patients with rheumatoid arthritis. Int J Rheumatol. 2014;2014:523897. doi: 10.1155/2014/523897. Epub 2014 Aug 17.</mixed-citation><mixed-citation xml:lang="en">Kuo D, Crowson CS, Gabriel SE, et al. Hyperuricemia and incident cardiovascular disease and noncardiac vascular events in patients with rheumatoid arthritis. Int J Rheumatol. 2014;2014:523897. doi: 10.1155/2014/523897. Epub 2014 Aug 17.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Petsch C, Aranjo EG, Engebrecht M, et al. Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia. Semin Arthritis Rheum. 2016 Jun;45(6):663-8. doi: 10.1016/j.semarthrit.2015.11.014. Epub 2015 Dec 2.</mixed-citation><mixed-citation xml:lang="en">Petsch C, Aranjo EG, Engebrecht M, et al. Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia. Semin Arthritis Rheum. 2016 Jun;45(6):663-8. doi: 10.1016/j.semarthrit.2015.11.014. Epub 2015 Dec 2.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wang P, Smith SE, Garg K, et al. Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT. RMD Open. 2018 Mar 9;4(1):e000593. doi: 10.1136/rmdopen-2017-000593. eCollection 2018.</mixed-citation><mixed-citation xml:lang="en">Wang P, Smith SE, Garg K, et al. Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT. RMD Open. 2018 Mar 9;4(1):e000593. doi: 10.1136/rmdopen-2017-000593. eCollection 2018.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Madej M, Morgiel E, Luczak A, et al. Coexistence of systemic sclerosis and gout? Hyperuricemia in systemic sclerosis: case report and literature review. Ann Acad Med Stetin. 2012;58(1):28-32.</mixed-citation><mixed-citation xml:lang="en">Madej M, Morgiel E, Luczak A, et al. Coexistence of systemic sclerosis and gout? Hyperuricemia in systemic sclerosis: case report and literature review. Ann Acad Med Stetin. 2012;58(1):28-32.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Weatherald J, Montani D, Jevnikar M, et al. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev. 2019 Jul 31;28(153):190023. doi: 10.1183/16000617.0023-2019. Print 2019 Sep 30.</mixed-citation><mixed-citation xml:lang="en">Weatherald J, Montani D, Jevnikar M, et al. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev. 2019 Jul 31;28(153):190023. doi: 10.1183/16000617.0023-2019. Print 2019 Sep 30.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bruce IN, Gladman DD. Hyperuricemia in psoriatic arthritis. J Clin Rheumatol. 2000 Feb;6(1):6-9.</mixed-citation><mixed-citation xml:lang="en">Bruce IN, Gladman DD. Hyperuricemia in psoriatic arthritis. J Clin Rheumatol. 2000 Feb;6(1):6-9.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">AlJohani R, Polachek A, Ye JY, et al. Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. J Rheumatol. 2018 Feb;45(2):213-17. doi: 10.3899/jrheum.170384. Epub 2017 Dec 1.</mixed-citation><mixed-citation xml:lang="en">AlJohani R, Polachek A, Ye JY, et al. Characteristic and outcome of psoriatic arthritis patients with hyperuricemia. J Rheumatol. 2018 Feb;45(2):213-17. doi: 10.3899/jrheum.170384. Epub 2017 Dec 1.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu J, Li A, Jia E, et al. Monosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joints in axial SpA: a dual-energy CT study. Arthritis Res Ther. 2017 May 2;19(1):83. doi: 10.1186/s13075-017-1286-0.</mixed-citation><mixed-citation xml:lang="en">Zhu J, Li A, Jia E, et al. Monosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joints in axial SpA: a dual-energy CT study. Arthritis Res Ther. 2017 May 2;19(1):83. doi: 10.1186/s13075-017-1286-0.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.</mixed-citation><mixed-citation xml:lang="en">Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Obermayr R, Temmi C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008 Dec; 19(12):2407-13. doi: 10.1681/ASN.2008010080. Epub 2008 Sep 17.</mixed-citation><mixed-citation xml:lang="en">Obermayr R, Temmi C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008 Dec; 19(12):2407-13. doi: 10.1681/ASN.2008010080. Epub 2008 Sep 17.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">House AA, Silva Oliveira S, Ronco C. Anti-inflammatory drugs and the kidney. Int J Artif Organs. 2007 Dec;30(12):1042-6. doi: 10.1177/039139880703001203.</mixed-citation><mixed-citation xml:lang="en">House AA, Silva Oliveira S, Ronco C. Anti-inflammatory drugs and the kidney. Int J Artif Organs. 2007 Dec;30(12):1042-6. doi: 10.1177/039139880703001203.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Schlesinger N, Schumacher HR Jr, Beutler AM. Serum uric acid in acute gout. Ann Rheum Dis. 1998 Jul;57(7):443-4. doi: 10.1136/ard.57.7.443.</mixed-citation><mixed-citation xml:lang="en">Schlesinger N, Schumacher HR Jr, Beutler AM. Serum uric acid in acute gout. Ann Rheum Dis. 1998 Jul;57(7):443-4. doi: 10.1136/ard.57.7.443.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002 Sep;29(9):1950-3.</mixed-citation><mixed-citation xml:lang="en">Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002 Sep;29(9):1950-3.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hasikova L, Pavlikova M, Hulejova H, et al. Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. Rheumatol Int. 2019 Oct;39(10):1749-57. doi: 10.1007/s00296-019-04394-6. Epub 2019 Jul 31.</mixed-citation><mixed-citation xml:lang="en">Hasikova L, Pavlikova M, Hulejova H, et al. Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. Rheumatol Int. 2019 Oct;39(10):1749-57. doi: 10.1007/s00296-019-04394-6. Epub 2019 Jul 31.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно- практическая ревматология. 2017; 55(6):600-9.</mixed-citation><mixed-citation xml:lang="en">Eliseev MS. Updated EULAR guidelines for the management of gout. Comments on certain items. Nauchno-Prakticheskaya Revmatologiya. 2017;55(6):600-9. (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
